Canaccord Genuity Reaffirms Buy Rating on Zeltiq Aesthetics (ZLTQ)

By admin | 6 years ago

Zeltiq Aesthetics (NASDAQ: ZLTQ)‘s stock had its “buy” rating reiterated by investment analysts at Canaccord Genuity in a note issued to investors on Wednesday.

Zeltiq Aesthetics traded down 0.35% on Wednesday, hitting $5.76. Zeltiq Aesthetics has a 1-year low of $5.35 and a 1-year high of $17.41. The company’s market cap is $195.9 million.

A number of other analysts have also recently weighed in on ZLTQ. Analysts at Goldman Sachs (NYSE: GS) downgraded shares of Zeltiq Aesthetics from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, March 7th. Analysts at JPMorgan Chase (NYSE: JPM) downgraded shares of Zeltiq Aesthetics from an “overweight” rating to a “neutral” rating in a research note to investors on Wednesday, March 7th.

ZELTIQ Aesthetics, Inc. (ZELTIQ) is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform.

About the author